Ensign Peak Advisors, Inc Neurocrine Biosciences Inc Transaction History
Ensign Peak Advisors, Inc
- $55.3 Billion
- Q4 2024
A detailed history of Ensign Peak Advisors, Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 173,694 shares of NBIX stock, worth $19.1 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
173,694
Previous 174,835
0.65%
Holding current value
$19.1 Million
Previous $20.1 Million
17.79%
% of portfolio
0.04%
Previous 0.04%
Shares
21 transactions
Others Institutions Holding NBIX
# of Institutions
656Shares Held
96.6MCall Options Held
282KPut Options Held
281K-
Black Rock Inc. New York, NY14.2MShares$1.56 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.11 Billion0.02% of portfolio
-
State Street Corp Boston, MA4.89MShares$537 Million0.03% of portfolio
-
Dodge & Cox San Francisco, CA3.02MShares$331 Million0.26% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.54MShares$278 Million0.06% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $10.5B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...